The changing profile of Ph-positive chronic myeloid leukemia at presentation: Possible impact of earlier diagnosis on survival

Haematologica

Volumn 84, Issue 4, 1999, Pages 324-327

  Cervantes, Francisco ^a   Hernández Boluda, Juan Carlos ^b   Ferrer, Ana ^b   Cid, Joan ^b   Montserrat, Emilio ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

Chronic myeloid leukemia; Natural history; Presenting features; Survival

Indexed keywords

ADULT; ARTICLE; CELL INFILTRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HEPATOMEGALY; HUMAN; HUMAN TISSUE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PH; SPLENOMEGALY; SURVIVAL RATE;

EID: 0345062285     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Spiers ASD. The clinical features of chronic granulocytic leukaemia. Clin Haematol 1977; 6:77-95.
2. Cortés J, Kantarjian HM, Giralt S, Talpaz M. Natural history and staging of chronic myelogenous leukaemia. Bailliére Clin Haematol 1997; 10:277-90.
3. Kantarjian HM, Giles FG, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin N 1998; 12:31-80.
4. Cervantes F, Villamor N, Esteve J, et al. "Lymphoid" blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol 1998; 100:123-8.
5. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63:789-99.
6. Kaplan G, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Ass 1958; 53:457-80.
7. Peto R, Pike MC. Conservation of the approximation E(O-E2)/E in the logrank test for survival data on tumor incidence data. Biometrics 1973; 29:579-84.
8. Pearson TC. Primary thrombocythaemia: diagnosis and management. BrJ Haematol 1991; 78:145-8.
9. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 1998; 60:101-5.
10. Hehlmann H, Heimpel J, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 1993; 82:398-407.
11. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon-α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820-5.
12. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122:254-61.
13. Carella AM, Frassoni F, Melo J, et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 1997; 82:478-95.
14. Zuffa E, Bandini G, Bonini A, et al. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 1998; 83:231-6.